Business Context and Reporting Period
Company: IMPACT BIOMEDICAL INC. (NYSE American: IBO)
Filing Type: Form 8-K (Current Report)
Reporting Date: June 23, 2025 (Event Date: June 21, 2025)
Event: Entry into a Material Definitive Agreement for a reverse merger and share exchange.
On June 21, 2025, Impact BioMedical Inc. ("Impact") entered into a Merger and Share Exchange Agreement with Dr Ashleys Limited ("PubCo") and related entities. The transaction involves a reverse merger where Impact will become a subsidiary of PubCo and be renamed "Dr Ashleys USA Inc." The deal is structured as a reverse stock split followed by an exchange of Impact shares for PubCo ordinary shares.
Key Financial Metrics and Transaction Terms
This filing details a corporate restructuring rather than operational financial results. No revenue, profit, or cash flow data for the reporting period is provided in this document.
- Merger Consideration: Existing Impact shareholders will receive PubCo ordinary shares representing 4.80% of the total issued and outstanding PubCo ordinary shares at closing.
- Share Exchange: The Dr Ashleys Shareholder will receive PubCo ordinary shares representing 94.20% of the total issued and outstanding PubCo ordinary shares.
- Other Issuances: BMI Capital International LLC will receive shares representing 1.00% of the total issued and outstanding PubCo ordinary shares.
- Debt and Liquidity Conditions: Closing is conditioned on Impact having net cash of at least $10,000 and net debt of $0 at the Closing.
- Stockholder Support: Stockholders holding 86.81% of Impact's shares (on an as-converted basis) have executed voting agreements to support the transaction.
Material Changes and Governance
The filing announces a fundamental change in corporate structure and control:
- Corporate Identity: Impact will be renamed "Dr Ashleys USA Inc." and become a wholly-owned subsidiary of PubCo.
- Management Change: The current board of directors and officers of Impact will resign. The new board and management team will be designated by Dr Ashleys Cayman.
- Capital Structure: All outstanding Impact Series A Preferred Stock will convert to common stock. In-the-money options and warrants will be cancelled and converted to common stock prior to the exchange.
- Reverse Stock Split: A reverse stock split of Impact's common stock will occur at a ratio to be mutually agreed upon prior to the effective time.
Guidance, Risks, and Conditions
Conditions to Closing: The transaction is subject to customary conditions, including stockholder approval from both Impact and Dr Ashleys Cayman, NYSE American listing approval for PubCo shares, and the absence of a material adverse effect.
Risks and Contingencies:
- Termination Rights: Either party may terminate the agreement upon a breach of representations, failure to obtain stockholder approval, or by mutual consent.
- Forward-Looking Risks: Risks include failure to obtain stockholder approval, inability to satisfy closing conditions, unexpected costs or delays, and potential disruption to business operations or retention of key personnel.
- Superior Proposals: Boards may change their recommendation if a superior proposal is received, subject to notice and negotiation periods.
Management Commentary: The filing states that the Merger Agreement includes representations and warranties made solely for the purpose of the agreement and should not be relied upon as establishing factual matters outside of that context.
Investor Verification Checklist
- Verify the final reverse stock split ratio to be mutually agreed upon by Impact and Dr Ashleys Cayman.
- Confirm the outcome of the required stockholder votes for both Impact and Dr Ashleys Cayman.
- Monitor the status of the NYSE American listing approval for PubCo shares.
- Review the upcoming joint proxy statement/prospectus for detailed financial information on Dr Ashleys and the combined entity.
- Confirm that Impact meets the closing condition of having net cash of at least $10,000 and net debt of $0.